Alexander Donald Macrae's Insider Trades & SAST Disclosures
Alexander Donald Macrae's most recent trade in Sangamo Therapeutics Inc was a trade of 126,950 Common Stock done at an average price of $0.8 . Disclosure was reported to the exchange on April 22, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Alexander Donald Macrae.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, PRESIDENT, CEO AND DIRECTOR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.78 per share. | 22 Apr 2025 | 126,950 | 2,325,898 (2%) | 0% | 0.8 | 98,551 | Common Stock |
| Sangamo Therapeutics Inc | Macrae Alexander Donald | Director, PRESIDENT, CEO AND DIRECTOR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 1,750,000 | 1,750,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Donald Alexander Macrae | Director, PRESIDENT, CEO AND DIRECTOR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2025 | 375,000 | 2,452,848 (2%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, PRESIDENT, CEO AND DIRECTOR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.96 per share. | 24 Feb 2025 | 10,663 | 2,077,848 (1%) | 0% | 1.0 | 10,195 | Common Stock |
| Sangamo Therapeutics Inc | Alexander Macrae Donald | Director, PRESIDENT, CEO AND DIRECTOR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.00 per share. | 24 Feb 2025 | 7,488 | 2,088,511 (1%) | 0% | 1 | 7,488 | Common Stock |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, PRESIDENT, CEO AND DIRECTOR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.15 per share. | 22 Jan 2025 | 412,584 | 2,095,999 (1%) | 0% | 1.2 | 474,472 | Common Stock |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, PRESIDENT, CEO AND DIRECTOR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.94 per share. | 24 Nov 2024 | 10,642 | 2,508,583 (2%) | 0% | 1.9 | 20,645 | Common Stock |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, PRESIDENT, CEO AND DIRECTOR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.88 per share. | 24 Nov 2024 | 7,473 | 2,519,225 (2%) | 0% | 1.9 | 14,049 | Common Stock |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, PRESIDENT, CEO AND DIRECTOR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.86 per share. | 24 Aug 2024 | 7,492 | 2,526,698 (2%) | 0% | 0.9 | 6,443 | Common Stock |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, PRESIDENT, CEO AND DIRECTOR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.86 per share. | 24 Aug 2024 | 5,261 | 2,534,190 (2%) | 0% | 0.9 | 4,524 | Common Stock |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, PRESIDENT, CEO AND DIRECTOR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.60 per share. | 24 May 2024 | 7,492 | 2,539,451 (2%) | 0% | 0.6 | 4,495 | Common Stock |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, PRESIDENT, CEO AND DIRECTOR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.60 per share. | 24 May 2024 | 5,261 | 2,546,943 (2%) | 0% | 0.6 | 3,157 | Common Stock |
| Sangamo Therapeutics Inc | Donald Macrae Alexander | Director, PRESIDENT, CEO AND DIRECTOR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.13 per share. | 24 Feb 2024 | 24,157 | 2,552,204 (2%) | 0% | 1.1 | 27,297 | Common Stock |
| Sangamo Therapeutics Inc | Donald Macrae Alexander | Director, PRESIDENT, CEO AND DIRECTOR | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.13 per share. | 24 Feb 2024 | 16,115 | 2,576,361 (2%) | 0% | 1.1 | 18,210 | Common Stock |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, PRESIDENT, CEO AND DIRECTOR | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jan 2024 | 2,000,000 | 2,592,476 (2%) | 1% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, President, CEO and Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.77 per share. | 25 Aug 2023 | 10,411 | 602,887 (0%) | 0% | 0.8 | 8,016 | Common Stock |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, President, CEO and Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.33 per share. | 25 May 2023 | 10,411 | 613,298 (0%) | 0% | 1.3 | 13,847 | Common Stock |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, President, CEO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 734,050 | 734,050 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, President, CEO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 157,300 | 678,476 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, President, CEO and Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.66 per share. | 24 Feb 2023 | 54,767 | 623,709 (0%) | 0% | 2.7 | 145,680 | Common Stock |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, President, CEO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 604,800 | 604,800 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, President, CEO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 224,000 | 521,176 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, President, CEO and Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.90 per share. | 25 Feb 2022 | 49,890 | 297,176 (0%) | 0% | 5.9 | 294,351 | Common Stock |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 276,750 | 276,750 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 138,375 | 347,066 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.19 per share. | 25 Feb 2021 | 35,311 | 208,691 (0%) | 0% | 11.2 | 395,130 | Common Stock |
| Sangamo Therapeutics Inc | Alexander Donald Macrae | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.95 per share. | 24 Jan 2021 | 3,977 | 244,002 (0%) | 0% | 14.9 | 59,456 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges